• ANA ± zoledronic acid had lower incidence of serious adverse events than TAM ± zoledronic acid (1% vs 7% endometrial hyperplasia, 1% vs 8% uterine polyp, 2% vs 4% uterine D&C, <1% vs 2% endometrial disorder) • ANA vs TAM had higher rate of non-serious adverse effects (33% vs 23% bone pain, 19% vs 8% arthralgia, 8% vs 2% muscle rigidity, 7% vs 3% arthropathy, 2% vs <1% joint stiffness) • OS, age >40 y: HR=0.57, p=0.057 • Addition of zoledronic acid to endocrine therapy improved DFS overall and for age >40 y but not <40 y • Zoledronic acid increased frequency of non-serious adverse effects (bone pain, pyrexia, joint stiffness) • Endocrine therapy alone (no zoledronic acid) caused significant loss of bone mineral density (BMD) at lumbar spine and trochanter (p<0.0001) at 36 mo • Without zoledronic acid, ANA caused greater BMD loss than TAM at 36 mo at lumbar spine (-13.6% vs -9.0%, p<0.0001) • 2 y after completion of treatment, pts without zoledronic acid still had decreased BMD compared with baseline, whereas pts with zoledronic acid had stable BMD at 36 mo and increased BMD at 60 mo compared with baseline TAM: mean increase from baseline in lumbar spine BMD of 1.2% at 12 mo and 0.2% at 24 mo. EXE: mean decrease from baseline of 2.6% after 12 mo and 3.5% after 24 mo (p=0.0001 at both time points). Changes in BMD from baseline at the total hip were also significantly different between EXE and TAM (p<0.05 at both time points). • Bone loss at hip: 1 y: -0.62% vs -1.66%, p=0.01
Effect
• Bone loss at hip, 2 y: -1.93% vs -2.71(p=0.10)
• Bone loss at L spine, 1 y: -0.59% vs -1.88% (p=0.32)
• Bone loss at L spine, 2 y: -0.92% vs -2.39% (p=0.08)
Group B: BMD increased in all groups despite EXE or ANA (effect of bisphosphonate + vitamin D + calcium)
• BMD change, hip, 1 y: 0.61% vs 0.83% (p=0.23)
• BMD change, hip, 2 y: 2.09% vs 0.00% (p=0.28)
• BMD change, L spine, 1 y: 3.75% vs 2.60% (p=0.67)
• BMD change, L spine, 2 y: 2.11% vs 3.72% (p=0.26) TEAM Japan: N SAS BC04 lipid substudy 45 EXE (5 y) vs TAM (2.5−3 y)→ EXE (2−2.5 y); 5 y total 52 52 Changes in lipid profiles with tamoxifen were relatively favourable, whereas exemestane and anastrozole had no clinically significant effect on serum lipids; tamoxifen may be a treatment choice for pts at high risk
Published by Multimed Inc. The LHRH agonist's meta-analysis authors suggest LHRH agonists are equally effective as chemotherapy regimens used, and LHRH added to chemotherapy has additional benefit in female pts aged ≤40 y. In these pts, chemotherapy is less likely to induce permanent amenorrhea than in older pts. This may especially be the case with modern non-CMF-based chemotherapy for which permanent amenorrhea after treatment seems less common.
